Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant |
| |
Authors: | Cassandra D Kelly Chris O'Loughlin Frank B Gelder Johnny W Peterson Laurie E Sower Nick M Cirino |
| |
Institution: | (1) New York State Department of Health, Biodefense Laboratory, Wadsworth Center, Albany, NY, USA;(2) Department of Biomedical Sciences, SUNY at Albany, School of Public Health, Albany, NY, USA;(3) Virionyx Corporation Ltd, Auckland, NZ, USA;(4) The University of Texas Medical Branch, Galveston, TX, USA |
| |
Abstract: | Background There is a clear need for vaccines and therapeutics for potential biological weapons of mass destruction and emerging diseases.
Anthrax, caused by the bacterium Bacillus anthracis, has been used as both a biological warfare agent and bioterrorist weapon previously. Although antibiotic therapy is effective
in the early stages of anthrax infection, it does not have any effect once exposed individuals become symptomatic due to B. anthracis exotoxin accumulation. The bipartite exotoxins are the major contributing factors to the morbidity and mortality observed
in acute anthrax infections. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|